Summary Box: FDA expands approval of J&J drug

(AP) WASHINGTON - FDA OK: The Food and Drug Administration on Monday approved the drug Zytiga for a new group of prostate cancer patients who have not yet received chemotherapy.

FAMILIAR FACE: The FDA previously approved the pill from Johnson & Johnson for men with prostate cancer who have already taken the chemotherapy drug docetaxel.

HALTING HORMONES: Zytiga works be decreasing the male hormone testosterone, which spurs growth of prostate tumors.